Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus paclitaxel + carboplatin for advanced or recurrent endometrial cancer
ACTRN12619000900112Phase 3Completed
- Sponsor
- The University of Sydney
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) and endometrial carcinosarcoma comparing Paclitaxel + carboplatin + placebo with Paclitaxel + carboplatin + atezolizumab (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Sep 2020; status: completed.
02
Drugs
atezolizumab
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on ACTRN12619000900112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000900112.